Merck Sharp + Dohme Corp.

Msd K.k.

Sachin Lohani

Masashi Kawasaki

Shinji Kato

Taketo Ikeno

Fuyuki Yamamoto

Yaling Wang

Sachin Mittal

Michael J McNevin

Sergei Pechenov

Himanshu Bhattacharjee

Hisaki Kojima

Shuntaro Furukawa

Daniel Hong Yin

Suzanne M D'Addio

Naotaka Sawada

Wataru Minagawa

Michael Mcnevin

Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.

Pharmaceutical compositions of a peptide

The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.

Pharmaceutical salts of an orexin receptor antagonist

The present invention relates to a process for producing a hydrate of 3-(2,6-dichlorophenyl)-4-imino-7-[(2'-methyl-2&#x2032;,3&#x2032;-dihydro-1&#x2032;H-spiro[cyclopropane-1,4&#x2032;-isoquinolin]-7&#x2032;-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (Compound A) or of a pharmaceutically acceptable salt of Compound A and a crystalline form of Compound A or of a pharmaceutically acceptable salt of Compound A, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.

Process for producing bicycloaniline derivatives

Growing community of inventors

Annandale, NJ, United States of America

Sachin Lohani